TWST:NSD-Twist Bioscience Corp (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 49.26

Change

-1.71 (-3.35)%

Market Cap

USD 2.94B

Volume

0.75M

Analyst Target

USD 75.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-24 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+5.35 (+1.09%)

USD 41.65B
ICLR ICON PLC

+0.24 (+0.08%)

USD 26.38B
ILMN Illumina Inc

+0.78 (+0.74%)

USD 17.24B
NTRA Natera Inc

-1.38 (-1.24%)

USD 13.49B
MEDP Medpace Holdings Inc

+19.01 (+4.69%)

USD 12.38B
EXAS EXACT Sciences Corporation

+0.33 (+0.75%)

USD 7.74B
RDNT RadNet Inc

+0.78 (+1.34%)

USD 4.31B
GH Guardant Health Inc

-0.34 (-1.16%)

USD 3.66B
NEOG Neogen Corporation

-0.03 (-0.19%)

USD 3.63B
SHC Sotera Health Co

+0.07 (+0.59%)

USD 3.21B

ETFs Containing TWST

ARCG:LSE ARK Genomic Revolution UC.. 9.48 % 0.00 %

-5.63 (-1.60%)

USD 2.30M
EDOC:LSE Global X Telemedicine & D.. 4.07 % 0.00 %

-0.05 (-1.60%)

USD 4.59M
EDOG:LSE Global X Telemedicine & D.. 4.07 % 0.00 %

-0.05 (-1.60%)

USD 0.14M
WBIO:LSE WisdomTree BioRevolution .. 4.05 % 0.00 %

-3.10 (-1.60%)

USD 2.97M
WDNA 3.93 % 0.00 %

N/A

N/A
WDNA:LSE WisdomTree BioRevolution .. 3.79 % 0.00 %

-0.03 (-1.60%)

USD 2.97M
WRNA:XETRA WisdomTree BioRevolution .. 3.33 % 0.00 %

-0.06 (-1.60%)

USD 2.77M
CDNA:CA CI Bio-Revolution ETF 3.06 % 0.00 %

N/A

CAD 5.70M
XBI SPDR® S&P Biotech ETF 1.49 % 0.35 %

+0.67 (+-1.60%)

USD 6.65B
ARKG 0.00 % 0.75 %

N/A

N/A
FYC First Trust Small Cap Gro.. 0.00 % 0.70 %

+0.52 (+-1.60%)

USD 0.27B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

+2.29 (+-1.60%)

USD 1.01B
FYX:LSE 0.00 % 0.00 %

N/A

N/A
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

-0.02 (-1.60%)

USD 0.02B
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

+0.01 (+-1.60%)

USD 0.05B
IBBJ 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 33.64% 93% A 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 33.64% 93% A 88% B+
Trailing 12 Months  
Capital Gain 179.57% 100% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 179.57% 100% F 98% N/A
Trailing 5 Years  
Capital Gain 70.75% 72% C 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 70.75% 72% C 77% C+
Average Annual (5 Year Horizon)  
Capital Gain 68.05% 89% A- 93% A
Dividend Return 68.05% 89% A- 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 175.22% 15% F 8% B-
Risk Adjusted Return 38.84% 81% B- 71% C-
Market Capitalization 2.94B 78% C+ 84% B

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector